Physician profile
Vasudha Dhar
NPI 1659574770
$19,553.85
in general payments reported to CMS, 2019-2025
35 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,236 · 2020: $4,514 · 2021: $1,367 · 2022: $1,368 · 2023: $1,159 · 2024: $1,540 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,013 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $16.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $16.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,201.38 | 2019-2020 | |
| Abbvie INC. | $2,588.68 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,659.37 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $795.81 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $603.34 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $487.82 | 2019-2025 | Entyvio |
| Redhill Biopharma INC. | $476.58 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Celgene Corporation | $459.34 | 2021-2024 | Zeposia |
| Vivus LLC | $440.23 | 2019-2025 | Qsymia, Pancreaze |
| Phathom Pharmaceuticals, INC. | $367.77 | 2024-2025 | Voquezna |
| Genzyme Corporation | $298.35 | 2022-2025 | |
| Ardelyx, INC. | $293.53 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $276.34 | 2019-2025 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $214.80 | 2019-2022 | |
| Madrigal Pharmaceuticals | $206.34 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $201.27 | 2019-2023 | Dificid |
| Pfizer INC. | $175.52 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $104.67 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $84.64 | 2022 | |
| Concordia Pharmaceuticals INC. | $84.24 | 2019 | |
| Nestle Healthcare Nutrition INC. | $81.67 | 2020-2022 | |
| Lilly USA, LLC | $78.29 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $74.56 | 2024-2025 | Bylvay, Iqirvo |
| Gilead Sciences, INC. | $56.92 | 2021-2025 | |
| Celltrion USA INC. | $52.01 | 2024-2025 | Vegzelma, Zymfentra |
| Echosens North America, INC. | $28.04 | 2021-2022 | |
| Intra-Sana Laboratories | $27.71 | 2022 | |
| Alfasigma USA, INC. | $27.58 | 2020-2021 | |
| Novo Nordisk INC | $23.90 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $16.85 | 2024 | |
| Ferring Pharmaceuticals INC. | $14.29 | 2019 | |
| Ethicon US, LLC | $14.03 | 2021 | |
| Daiichi Sankyo INC. | $13.77 | 2022 | |
| Meridian Bioscience INC. | $12.66 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasudha Dhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.